Comparative Pharmacology
Head-to-head clinical analysis: SANCTURA XR versus SCOPOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SANCTURA XR versus SCOPOLAMINE.
SANCTURA XR vs SCOPOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the action of acetylcholine at these receptors in the central nervous system and periphery.
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
1.5 mg transdermal patch applied to postauricular skin every 72 hours; for prevention of motion sickness, apply 4-5 hours before exposure. Alternatively, 0.3-0.65 mg intramuscularly or intravenously every 6-8 hours as needed; or 0.4-0.8 mg subcutaneously. Oral dose: 0.4-0.8 mg every 6-8 hours as needed.
None Documented
None Documented
Clinical Note
moderateScopolamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine."
Clinical Note
moderateScopolamine + Nefazodone
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone."
Clinical Note
moderateScopolamine + Stiripentol
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol."
Clinical Note
moderateScopolamine + Fesoterodine
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Terminal elimination half-life is approximately 2–4 hours in adults; in elderly or hepatic impairment, half-life may be prolonged.
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of elimination; biliary/fecal excretion accounts for the remainder.
Category C
Category A/B
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine."